Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

NCT04858958 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Furmonertinib 160mg
DRUG: Furmonertinib 240mg

Sponsor

Allist Pharmaceuticals, Inc.